Biophytis SA

About Biophytis SA

Biophytis is a pioneering biotechnology company focused on developing transformative therapies that impact longevity and target age-related diseases. Their mission is to help people live healthier longer by addressing biological resilience pathways to mitigate the effects of aging-related stress.

Products & Services

BIO101 (20-hydroxyecdysone):A small molecule administered orally for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy.

Macuneos (BIO201):A small molecule administered orally for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease.

Specialties

Age-related diseases Neuromuscular diseases (Sarcopenia, Duchenne Muscular Dystrophy) Retinal diseases (Dry AMD, Stargardt Disease) Biological resilience pathways Clinical trials for obesity and aging-related conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Bonds redeemable in cash and in new and existing shares (ORNANE) T: - FT: Bonds redeemable in cash and in new and existing shares (ORNANE)	A: 17280000 MR: - FA: up to €16 million FAN: 17280000	D: 2024-06-19 FD: 2024-06-19	1 investors
2	RT: Registered Direct Offering with concurrent private placement T: - FT: Registered Direct Offering with concurrent private placement	A: 3800000 MR: - FA: $3.8 million FAN: 3800000	D: 2023-07-19 FD: 2023-07-19	-
3	RT: Equity Financing (Capital Increase) T: - FT: Equity Financing (Capital Increase)	A: 2490900 MR: - FA: €2.3 million FAN: 2490900	D: 2023-05-11 FD: 2023-05-11	2 investors
4	RT: Equity Round T: - FT: Equity Round	A: 2000000 MR: - FA: approximately 2 million euros FAN: 2000000	D: 2023-05-10 FD: 2023-05-10	3 investors

Bonds redeemable in cash and in new and existing shares (ORNANE) Latest

2024-06-19

$17.3M

1 investor (Pro only)

Registered Direct Offering with concurrent private placement 2023-07-19

$3.8M

Equity Financing (Capital Increase) 2023-05-11

$2.5M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stanislas Veillet

President and Chief Executive Officer

C

Claude Allary

N

Nadine Coulm

Board Member

J

Jean Mariani

Medical Director

R

Roger A. Fielding

Professor

R

René Lafont

Scientific Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Biophytis SA Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised